Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Z7TM
|
||||
Former ID |
DNC008462
|
||||
Drug Name |
BMS-645737
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
Download2D MOL |
||||
Formula |
C20H20N8O
|
||||
Canonical SMILES |
CC1=CC2=CC(=CN=C2N1)NC3=NC=NN4C3=C(C(=C4)C5=NN=C(O5)C)C<br />(C)C
|
||||
InChI |
1S/C20H20N8O/c1-10(2)16-15(20-27-26-12(4)29-20)8-28-17(16)19(22-9-23-28)25-14-6-13-5-11(3)24-18(13)21-7-14/h5-10H,1-4H3,(H,21,24)(H,22,23,25)
|
||||
InChIKey |
OOQXPATWSOGSAV-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [1] | |
Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancer | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
VEGF binds to VEGFR leading to receptor dimerization | |||||
Integrin cell surface interactions | |||||
EPHA-mediated growth cone collapse | |||||
VEGFA-VEGFR2 Pathway | |||||
VEGFR2 mediated cell proliferationR-HSA-1296072:Voltage gated Potassium channels | |||||
WikiPathways | Focal Adhesion | ||||
Nifedipine Activity | |||||
Cardiac Progenitor Differentiation | |||||
Signaling by VEGF | |||||
AngiogenesisWP706:SIDS Susceptibility Pathways | |||||
Hematopoietic Stem Cell Differentiation | |||||
Potassium Channels | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9. Epub 2008 Mar 22.Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.